PT1928405E - Composições farmacêuticas para o tratamento de distúrbios do ouvido interno - Google Patents

Composições farmacêuticas para o tratamento de distúrbios do ouvido interno Download PDF

Info

Publication number
PT1928405E
PT1928405E PT05797324T PT05797324T PT1928405E PT 1928405 E PT1928405 E PT 1928405E PT 05797324 T PT05797324 T PT 05797324T PT 05797324 T PT05797324 T PT 05797324T PT 1928405 E PT1928405 E PT 1928405E
Authority
PT
Portugal
Prior art keywords
treatment
pharmaceutical compositions
inner ear
ear disorders
disorders
Prior art date
Application number
PT05797324T
Other languages
English (en)
Inventor
Thomas Meyer
Original Assignee
Auris Medical Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37019770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1928405(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auris Medical Ag filed Critical Auris Medical Ag
Publication of PT1928405E publication Critical patent/PT1928405E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00—Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Acoustics & Sound (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT05797324T 2005-09-28 2005-09-28 Composições farmacêuticas para o tratamento de distúrbios do ouvido interno PT1928405E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/010478 WO2007038949A1 (en) 2005-09-28 2005-09-28 Pharmaceutical compositions for the treatment of inner ear disorders

Publications (1)

Publication Number Publication Date
PT1928405E true PT1928405E (pt) 2014-10-20

Family

ID=37019770

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05797324T PT1928405E (pt) 2005-09-28 2005-09-28 Composições farmacêuticas para o tratamento de distúrbios do ouvido interno

Country Status (25)

Country Link
US (5) US20090246255A1 (pt)
EP (2) EP2792347A1 (pt)
JP (1) JP2009509982A (pt)
KR (1) KR101271263B1 (pt)
CN (1) CN101309667A (pt)
AU (1) AU2005337107B2 (pt)
BR (1) BRPI0520588B8 (pt)
CA (1) CA2620374C (pt)
CU (1) CU20080044A7 (pt)
CY (1) CY1115891T1 (pt)
DK (1) DK1928405T3 (pt)
EA (1) EA017264B1 (pt)
ES (1) ES2524994T3 (pt)
HR (1) HRP20140920T1 (pt)
IL (1) IL189622A (pt)
ME (1) ME01956B (pt)
NO (1) NO339356B1 (pt)
NZ (1) NZ566062A (pt)
PL (1) PL1928405T3 (pt)
PT (1) PT1928405E (pt)
RS (1) RS53591B1 (pt)
SI (1) SI1928405T1 (pt)
TN (1) TNSN08079A1 (pt)
WO (1) WO2007038949A1 (pt)
ZA (1) ZA200802762B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096518A2 (en) * 2005-03-04 2006-09-14 Neurosystec Corporation Improved gacyclidine formulations
EA017264B1 (ru) 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
WO2009006390A2 (en) 2007-07-03 2009-01-08 Charles Stark Draper Laboratory, Inc. Drug-eluting staples prosthesis
US9132087B2 (en) * 2008-04-21 2015-09-15 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
GB2461962B (en) * 2008-07-25 2011-02-16 Otonomy Inc Slow release NMDA receptor antagonist for otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
BRPI0915770A2 (pt) * 2008-07-14 2015-11-03 Otonomy Inc composição de modulação de apoptose de liberação controlada e métodos para o tratamento de distúrbios ótológicos
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN102105133B (zh) 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
WO2010048095A2 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
WO2010074992A2 (en) * 2008-12-22 2010-07-01 Otonomy, Inc. Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2409683A1 (en) 2010-07-06 2012-01-25 KRKA, D.D., Novo Mesto Stable aqueous formulations comprising poorly water soluble active ingredients
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
US10130514B2 (en) * 2011-09-26 2018-11-20 Incube Labs, Llc System and method for delivery of a therapeutic agent to the inner ear
EP2790686B1 (en) 2011-12-12 2021-03-10 Zilentin Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
IN2015DN03854A (pt) 2012-10-08 2015-10-02 Auckland Uniservices Ltd
US20140348787A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Methods and Compositions for Treating Ear Infections
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) * 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EP3984525A1 (en) * 2014-06-12 2022-04-20 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
BR112020014189B1 (pt) * 2018-01-10 2022-07-12 XWPharma Ltd. Composto, composição farmacêutica e uso do composto
JP7492917B2 (ja) 2018-02-09 2024-05-30 デシベル セラピューティクス インコーポレイテッド 抗白金化学保護剤を含む高張医薬組成物
JPWO2019160057A1 (ja) 2018-02-15 2021-02-04 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
WO2019186357A1 (en) * 2018-03-26 2019-10-03 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
AU2019262197A1 (en) 2018-05-04 2020-11-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US20200214976A1 (en) * 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
CN115942935A (zh) * 2020-08-18 2023-04-07 奥克伍德实验室有限责任公司 包括氯胺酮的微球制剂及其制备和使用方法
WO2022140636A1 (en) * 2020-12-22 2022-06-30 Otonomy, Inc. Gacyclidine otic formulations and uses thereof
US11753378B2 (en) 2021-04-19 2023-09-12 Zevra Therapeutics, Inc. Ketamine compounds and processes for making and using them
WO2023018966A1 (en) 2021-08-13 2023-02-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254124A (en) 1962-06-29 1966-05-31 Parke Davis & Co Aminoketones and methods for their production
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
DE69529987T2 (de) * 1994-07-15 2004-01-15 Hitachi Ltd Elektronischer energiefilter
US5863927A (en) * 1994-09-22 1999-01-26 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
DE19528388A1 (de) 1995-08-02 1997-02-06 Hans Peter Prof Dr Med Zenner Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
WO1997038698A1 (en) 1996-04-18 1997-10-23 University Technology Corporation Methods for treating middle and inner ear disorders
WO1998010757A2 (en) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of functional n-methyl-d-aspartate antagonists to ameliorate or prevent aminoglycoside-induced ototoxicity
US6045528A (en) * 1997-06-13 2000-04-04 Intraear, Inc. Inner ear fluid transfer and diagnostic system
US6309410B1 (en) 1998-08-26 2001-10-30 Advanced Bionics Corporation Cochlear electrode with drug delivery channel and method of making same
DE19853299C2 (de) * 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
JP2003500368A (ja) * 1999-05-24 2003-01-07 ソーナス ファーマシューティカルス，インコーポレイテッド 溶解度が不十分な薬剤のためのエマルジョンビヒクル
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
DE19936719A1 (de) 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
JP2001187737A (ja) 1999-10-18 2001-07-10 Toyama Chem Co Ltd 聴力改善剤
AU2001257295A1 (en) 2000-05-01 2001-11-12 Georgetown University In vivo assay for identifying nucleic acid sequences involved in alveolar loss, development and nucleic acid sequences identified thereby
DE10025238A1 (de) * 2000-05-22 2001-11-29 Gruenenthal Gmbh Verwendung substituierter 1-Amino-5-phenylpentan-3-ol- und/oder 1-Amino-6-phenylhexan-3-ol- Verbindungen als Arzneimittel
BRPI0002693B8 (pt) 2000-06-19 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
DE10044649A1 (de) * 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
DE10124953A1 (de) 2001-05-21 2002-12-12 Marlies Knipper Substanz für die therapeutische Behandlung von Tinnitus
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030143195A1 (en) * 2002-01-30 2003-07-31 Pinsker Judy Senior Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
US6638081B2 (en) * 2002-03-22 2003-10-28 Hon Hai Precision Ind. Co., Ltd. Electrical connector
US20040037311A1 (en) 2002-08-07 2004-02-26 Phonex Broadband Corporation Digital narrow band power line communication system
JP2006502158A (ja) * 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
US6969383B2 (en) * 2002-09-27 2005-11-29 Medtronic, Inc. Method for treating severe tinnitus
DE50312412D1 (en) * 2002-11-12 2010-03-25 Gruenenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
EP1438942A1 (en) 2003-01-17 2004-07-21 Schering Oy An otorhinological drug delivery device
CN100581621C (zh) 2003-05-16 2010-01-20 拉瓦勒大学 Cns氯化物调节及其用途
EP1699431B1 (en) 2003-12-12 2015-08-19 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
EA017264B1 (ru) 2005-09-28 2012-11-30 Аурис Медикаль Аг Применение композиции арилциклоалкиламида для получения лекарственного препарата для лечения нарушения внутреннего уха

Also Published As

Publication number Publication date
DK1928405T3 (da) 2014-12-15
KR101271263B1 (ko) 2013-06-07
IL189622A (en) 2016-10-31
SI1928405T1 (sl) 2014-12-31
ZA200802762B (en) 2015-11-25
JP2009509982A (ja) 2009-03-12
EA200800798A1 (ru) 2008-10-30
US9066865B2 (en) 2015-06-30
NO20081919L (no) 2008-04-22
IL189622A0 (en) 2008-06-05
ES2524994T3 (es) 2014-12-16
ME01956B (me) 2015-05-20
RS53591B1 (en) 2015-02-27
WO2007038949A1 (en) 2007-04-12
HRP20140920T1 (hr) 2014-12-05
US20150265532A1 (en) 2015-09-24
US20150250719A1 (en) 2015-09-10
EA017264B1 (ru) 2012-11-30
CN101309667A (zh) 2008-11-19
AU2005337107A1 (en) 2007-04-12
TNSN08079A1 (en) 2009-07-14
US20150196569A1 (en) 2015-07-16
BRPI0520588A2 (pt) 2009-05-19
AU2005337107B2 (en) 2012-05-24
KR20080074093A (ko) 2008-08-12
BRPI0520588B1 (pt) 2018-07-10
NZ566062A (en) 2009-08-28
EP2792347A1 (en) 2014-10-22
CU20080044A7 (es) 2011-04-26
CA2620374A1 (en) 2007-04-12
PL1928405T3 (pl) 2015-03-31
CY1115891T1 (el) 2017-01-25
US20140364836A1 (en) 2014-12-11
BRPI0520588B8 (pt) 2021-05-25
NO339356B1 (no) 2016-12-05
CA2620374C (en) 2012-12-11
EP1928405A1 (en) 2008-06-11
EP1928405B1 (en) 2014-09-24
US20090246255A1 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
IL189622A0 (en) Pharmaceutical compositions for the treatment of inner ear disorders
IL191283A (en) Compositions for treating eye irregularities
TWI369987B (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL190913B (en) Preparations for the treatment of sweating disorders
EP1853295A4 (en) METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES
EP1940441A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
IL186578A0 (en) Compositions for treatment of neovascularization diseases
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
IL185052A0 (en) Treatment of bone disorders
ZA200706791B (en) Isoxazole combretasin derivatives for the treatment of disorders
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
ZA200801667B (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
HU0500145D0 (en) Composition for the treatment of oral diseases
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
EP1865952A4 (en) COMPOSITIONS CONTAINING HISTAMINES FOR THE TREATMENT OF ALLERGIES
IL190182A0 (en) 2-aminoalcohols for the treatment of neurodegenerative diseases
HUP0500685A2 (en) Pharmaceutical composition for the treatment of psychosis